Lead Product(s) : Radgocitabine,Venetoclax
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Delta-Fly Shows Initial Phase 1/2 Data for AML Combo Therapy
Details : DFP-10917 (radgocitabine) is a DNA polymerase inhibitor small molecule drug candidate which is being evaluated in combination with venetoclax for the treatment of acute myeloid leukemia.
Brand Name : DFP-10917
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 28, 2024
Lead Product(s) : Radgocitabine,Venetoclax
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Radgocitabine,Venetoclax
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Delta-Fly Initiates Enrollment for Ph I/II Combo-Study of DFP-10917 and Venetoclax in AML
Details : DFP-10917 (radgocitabine) is a DNA polymerase inhibitor small molecule drug candidate which is being evaluated in combination with venetoclax for the treatment of acute myeloid leukemia.
Brand Name : DFP-10917
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 10, 2024
Lead Product(s) : Radgocitabine,Venetoclax
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Radgocitabine,Venetoclax
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Delta-Fly Pharma Authorized to Conduct Phase I/II of DFP-10917 Combined with Venetoclax
Details : DFP-10917 (radgocitabine) is a DNA polymerase inhibitor small molecule drug candidate which is being evaluated in combination with venetoclax for the treatment of acute myeloid leukemia.
Brand Name : DFP-10917
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 08, 2024
Lead Product(s) : Radgocitabine,Venetoclax
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Radgocitabine,Venetoclax
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Delta-Fly Pharma Submits Phase I/II Protocol of DFP-10917 and Venetoclax for AML to FDA
Details : DFP-10917 (radgocitabine) is a DNA polymerase inhibitor small molecule drug candidate which is being evaluated in combination with venetoclax for the treatment of acute myeloid leukemia.
Brand Name : DFP-10917
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 11, 2024
Lead Product(s) : Radgocitabine,Venetoclax
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?